Advertisement

Topics

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz

12:03 EDT 8 Aug 2017 | Medscape

Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.
Reuters Health Information

Original Article: Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz

NEXT ARTICLE

More From BioPortfolio on "Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz"

Quick Search
Advertisement
 

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...